Replies to post #46 on China Shenghuo Pharmaceutical Holdings Inc (fka CK

[steeledge]

It's just a matter of time. One by one the sub-$1 biotechs are getting nice runs. None of those have earnings, many are listing deficient. Technically KUN still is but they at least have an accepted compliance plan from Amex. Regardless, this one is thin, profitable, and I am happy to own it from the low .50's